Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm C Pike

Showing results (161-170 of 252) with videos related to

Pageof 26
Sort By:
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
Obstetrics and Gynecology|April 8, 2016
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma RiskAlice W Lee, Roberta B Ness, Lynda D Roman, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Obstetrics and Gynecology|May 10, 2017
Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer ConsortiumSusan J Jordan, Renhua Na, Sharon E Johnatty, et al.
Plos One|June 16, 2011
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
Human Molecular Genetics|March 23, 2011
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer riskCeleste Leigh Pearce, Jennifer A Doherty, David J Van Den Berg, et al.
Cancer Research|February 21, 2006
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studiesHeather Spencer Feigelson, David G Cox, Howard M Cann, et al.
British Journal of Cancer|March 29, 2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association ConsortiumSuzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 17, 2007
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)Veronica Wendy Setiawan, Fredrick R Schumacher, Christopher A Haiman, et al.
International Journal of Epidemiology|April 10, 2013
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studiesWeiva Sieh, Shannon Salvador, Valerie McGuire, et al.
Pageof 26

Showing results (161-170 of 252) with videos related to

Sort By:
Pageof 26
Plos One|July 4, 2008
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3)Alpa V Patel, Iona Cheng, Federico Canzian, et al.
Obstetrics and Gynecology|April 8, 2016
Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma RiskAlice W Lee, Roberta B Ness, Lynda D Roman, et al.
JAMA Oncology|July 2, 2016
Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA MutationsCatherine A Shu, Malcolm C Pike, Anjali R Jotwani, et al.
Obstetrics and Gynecology|May 10, 2017
Breastfeeding and Endometrial Cancer Risk: An Analysis From the Epidemiology of Endometrial Cancer ConsortiumSusan J Jordan, Renhua Na, Sharon E Johnatty, et al.
Plos One|June 16, 2011
Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association ConsortiumGalina Lurie, Lynne R Wilkens, Pamela J Thompson, et al.
Human Molecular Genetics|March 23, 2011
Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer riskCeleste Leigh Pearce, Jennifer A Doherty, David J Van Den Berg, et al.
Cancer Research|February 21, 2006
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studiesHeather Spencer Feigelson, David G Cox, Howard M Cann, et al.
British Journal of Cancer|March 29, 2017
Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association ConsortiumSuzanne C Dixon, Christina M Nagle, Nicolas Wentzensen, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|November 17, 2007
CYP17 genetic variation and risk of breast and prostate cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3)Veronica Wendy Setiawan, Fredrick R Schumacher, Christopher A Haiman, et al.
International Journal of Epidemiology|April 10, 2013
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studiesWeiva Sieh, Shannon Salvador, Valerie McGuire, et al.
Pageof 26